Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $5.00 price target on shares of Trevena in a research note on Thursday, November 14th.

Trevena Trading Down 1.4 %

Trevena stock opened at $1.76 on Friday. The stock has a fifty day moving average price of $1.80 and a 200 day moving average price of $4.15. Trevena has a 52 week low of $1.13 and a 52 week high of $19.23. The firm has a market capitalization of $1.52 million, a P/E ratio of -0.04 and a beta of 1.08.

Trevena (NASDAQ:TRVN) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($5.79) EPS for the quarter. The firm had revenue of $0.28 million for the quarter. As a group, equities analysts predict that Trevena will post -23.04 EPS for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.